CSE/MYTC (CSE/MYTC)

Canadian Securities Exchange: CSE/MYTC · CAD

CA$0.01

+0.00 (0.0%)· Recorded snapshot

Market cap	157.6K
Shares out	31.5M
Volume	4,000
Beta	-7.71

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Market cap: 157.6K

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-29 19:55 UTC

Forward P/En/a

P25 11P50 16.8P75 23.9

Trailing P/En/a

P25 9.9P50 23.3P75 38.5

ROEn/a

P25 -104.1P50 -30P75 6.7

ROICn/a

P25 -55.9P50 -12.1P75 5

Benchmarks · 1M

S&P 500-0.5%

Nasdaq Composite-4.9%

Dow Jones Industrial Average+2.2%

Russell 2000+1.2%

All CSE/MYTC indicators

Market & fundamental data

Available fields

Groups with data

Currency

CAD

Showing 75 of 75 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	CAD
Country	Canada
Country code	CA
Exchange	Canadian Securities Exchange
Financial currency	CAD
First seen	2026-05-10
Founded	2008
Industry	Medical Devices
Is primary listing	Yes
ISIN number	CA62858B1085
Last refreshed	2026-10-29
Market cap	CAD 157,620
Price	CAD 0.01
Price currency	CAD
Sector	Healthcare
SIC code	3845
Stock price date	2026-04-27
Symbol	cse/MYTC
Website	https://myndtec.com

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	4
EPS growth years	3
Net income growth quarters	1
Net income growth years	3
Revenue growth years	0

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
WACC	-38.15%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1D price change	0%
1M price change	-75%
1M total return	-75%
1Y price change	-93.75%
1Y return CAGR	-93.76%
1Y total return	-93.75%
20-day SMA	CAD 0.02
3M price change	-50%
3M total return	-50%
3Y price change	-99.29%
3Y return CAGR	-80.73%
3Y total return	-99.29%
50-day SMA	CAD 0.13
52-week high	CAD 0.10
52-week high date	2025-12-08
52-week low	CAD 0.01
52-week low date	2026-04-27
All-time high	CAD 5.01
All-time high date	2022-03-18
All-time low	CAD 0.01
All-time low date	2025-11-28
Average true range (ATR)	CAD 0.03
Average volume	36.9K
Beta (1Y)	-7.19
Beta (2Y)	-7.34
Beta (5Y)	-7.71
Change from 52-week high	-95%
Change from 52-week low	0%
Change from all-time high	-99.9%
Change from all-time low	0%
Change from open	0%
Day's gap	0%
Dollar volume	CAD 20
High price	CAD 0.01
Low price	CAD 0.01
Monthly RSI	14.12
Open price	CAD 0.01
Previous close	CAD 0.01
Price vs 20-day SMA	-70.59%
Price vs 50-day SMA	-96.24%
Relative volume	0.11
RSI	25.62
Sharpe ratio	1.6
Sortino ratio	9.77
Volume	4K
Weekly RSI	0
YTD price change	-75%
YTD total return	-75%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Shares held by insiders	40.13%
Shares outstanding	31.5M

Deeper analysis on CSE/MYTC

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this CSE/MYTC report

Is a complete CSE/MYTC research report available?

No complete published report is available for cse/MYTC (CSE/MYTC) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.